nicorandil has been researched along with Heritable Pulmonary Arterial Hypertension in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, HW; Chen, YL; Chua, S; Chung, SY; Hsu, SY; Lee, FY; Leu, S; Lu, HI; Sheu, JJ; Sun, CK; Tsai, TH; Yip, HK; Zhen, YY | 1 |
| Hirata, Y; Morita, T; Nagai, R; Sahara, M; Sata, M | 1 |
2 other study(ies) available for nicorandil and Heritable Pulmonary Arterial Hypertension
| Article | Year |
|---|---|
Benefit of combined therapy with nicorandil and colchicine in preventing monocrotaline-induced rat pulmonary arterial hypertension.
Topics: Animals; Antihypertensive Agents; Aorta, Thoracic; bcl-2-Associated X Protein; Caspase 3; Cell Cycle Checkpoints; Cell Line; Colchicine; Connexin 43; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Heart Ventricles; Hypertension, Pulmonary; Lung; Male; Matrix Metalloproteinase 9; Monocrotaline; Myocytes, Smooth Muscle; NF-kappa B; Nicorandil; Nitric Oxide Synthase Type III; Rats; Rats, Sprague-Dawley; Smad3 Protein; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2013 |
Nicorandil attenuates monocrotaline-induced vascular endothelial damage and pulmonary arterial hypertension.
Topics: Animals; Antihypertensive Agents; Apoptosis; Blotting, Western; Caspase 3; Cells, Cultured; Drug Therapy, Combination; Endothelium, Vascular; Enzyme Inhibitors; Familial Primary Pulmonary Hypertension; Glyburide; Human Umbilical Vein Endothelial Cells; Humans; Hypertension, Pulmonary; Injections, Intraperitoneal; Male; MAP Kinase Signaling System; Monocrotaline; NG-Nitroarginine Methyl Ester; Nicorandil; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Random Allocation; Rats; Rats, Sprague-Dawley; Signal Transduction; Ventricular Pressure | 2012 |